Meet the Dynamic Visionaries and Leaders That You’ll Partner with When You Choose Veristat.

Patrick Flanagan
Chief Executive Officer
Patrick Flanagan is Chief Executive Officer at Veristat, responsible for the company’s business management and financial performance. In collaboration with company leaders, Patrick is responsible for the development and implementation of Veristat’s organizational goals and business strategies.
Patrick has built a 23-year career leading commercial growth, international expansion and financial & operational improvement initiatives for leading companies in the consulting, healthcare, and software fields including A.T. Kearney, Baxter International, Allegiance Healthcare and Oracle. Prior to joining Veristat, Patrick served as Chief Operating Officer of Certara and the General Manager of Certara’s Pharsight Consulting Services Group, a Vector Capital portfolio company engaged in the business of providing consulting services and software to pharmaceutical and biotechnology companies.
Patrick holds a BS in Business from Penn State University and an MBA with a concentration in Finance and Marketing from the Kellogg Graduate School of Management at Northwestern University. Patrick is also an active father, skier, golfer, occasional marathon runner and aging tri-athlete.

John P. Balser, Ph.D
President & Chief Statistical Officer
John Balser,
Prior to founding Veristat in 1994, John served as Vice President, Biostatistics, and Data Management at Medical & Technical Research Associates, Inc. He has held positions of increasing responsibility in the biostatistics departments at various pharmaceutical companies including E.R. Squibb, Biogen, and Miles.
John received his MS and

Barbara Balser, VMD
Executive Vice President & Chief Scientific Officer
Barbara Balser, VMD, co-founder, Executive Vice President and Chief Scientific Officer of Veristat, is primarily responsible for strategic planning and consulting, medical oversight, and production of regulatory submission documents. Barbara has more than 30 years of clinical research experience that encompasses both the pharmaceutical and contract research organization industries. Her experience includes oversight and production of Investigational New Drug (IND) applications, regulatory agency briefing documents, preparation for and representation at advisory panel meetings, and consultation across Phase 1 to 4 trials in multiple therapeutic areas with a specific focus in oncology and anti-infectives. Barbara has participated in the writing, oversight, and submission of multiple marketing applications to US, Canadian, Japanese, and European Union regulatory authorities. Prior to co-founding Veristat, Barbara served as Associate Director of Clinical Research at Medical & Technical Research Associates, Inc. where she was responsible for strategic planning, design, and management of clinical development programs; preparation and submission of regulatory applications; and scientific communications.
Barbara began her career in the pharmaceutical industry at Miles, Inc. (currently Bayer Corporation). In her capacity as Assistant Director of Clinical Research at Miles, Barbara assisted with strategic planning for the clinical development of anti-infective compounds from Phases 2 to 4 and with the planning, writing, and compilation of two successful NDAs for anti-infective products. Prior to joining the pharmaceutical and biotech industry, Barbara practiced veterinary medicine at a private veterinary hospital. Barbara holds a BS in Chemical Engineering from the University of Pennsylvania, School of Engineering and Applied Science, and a VMD from the University of Pennsylvania, School of Veterinary Medicine. When Barbara isn’t busy traveling the world for our clients, she enjoys spending time on the beach with a good book.

Jason Cash
Chief Financial Officer
As the Chief Financial Officer, Jason oversees all strategic and tactical matters as they relate to financial planning, budget management, and forecasting needs. Additionally, he drives the visibility of the financial data needed to inform and support the Company's operational and growth plans.
He joined Veristat with over 15 years of financial experience in the CRO industry. Before his current role, Jason served as VP of Finance at LabConnect and held several financial leadership roles at Covance, Inc. (a division of Labcorp) including Executive Director, Revenue & Project Analysis and Global Director, Financial Planning & Analysis.
Jason holds a BS in Business Management from North Carolina State University, an MA in Economics from Clemson University and an MS in Finance from Indiana University.

Cindy Henderson
Executive Vice President, Strategic Development
Cindy Henderson is the Executive Vice President, Strategic Development at Veristat overseeing the Proposals & Contracts functions as well as building and managing partner relationships and collaborating with the executive team on corporate growth strategies. With over 20 years of experience, Cindy concentrates on providing innovative functional and operational support to Veristat’s diverse, sponsor-based clinical studies. Cindy’s key areas of operational expertise include the ability to lend deep insight into the sequence of events clinical studies take as they advance toward the goal of product regulatory submission, the ability to effectively manage and assess client needs, and the ability to strategically outline the required resources for clinical programs. Cindy is a primary contributor in all tactical strategic planning both within Veristat and within client projects.
Prior to joining Veristat in 2007, Cindy served as the Senior Manager of Training, Innovations and Processes at Averion International Corporation where she led various initiatives to create and improve standard operating procedures, while implementing new technologies for data management and was a member of the integration team for several key corporate acquisitions. While at PAREXEL International Corporation as the Associate Director of Data Management, Cindy managed several international clinical trials, developed SOPs and processes, provided training and participated in software development, validation, and implementation efforts.
Outside of Veristat Cindy is a Supervising Judge for the North American Flyball Association (www.flyball.org). She also competes in this fun and fast paced sport with her two border collies and miniature Australian shepherd as part of the Weston Whirlwinds Flyball Team (www.wwflyball.org).

Shaheen Limbada
Executive Vice President, Global Clinical Operations
Shaheen Limbada is the Executive Vice President of Global Clinical Operations at Veristat. In this role, Mr. Limbada oversees patient recruitment, site engagement, site monitoring, and site management teams. With over 20 years of experience running clinical trials, he excels in the areas of organizational development and execution, patient recruitment and retention, clinical study conduct and governance, and drug safety monitoring.
He joined Veristat through the recent acquisition of Topstone Research, a Canadian-based CRO that he co-founded and held the position of Managing Director. Prior to Topstone, he worked in clinical operations, project management and leadership roles at various clinical research organizations (CROs) and pharmaceutical firms including Leo Pharma, Cetero Research and AstraZeneca.
Mr. Limbada graduated from the University of Toronto and quickly began his career in clinical trials with AstraZeneca Canada Inc. on.

Alecia Barbee
Executive Vice President, Operations
As Executive Vice President of Operations, Alecia provides strategic leadership for the Biometrics, Medical Writing, Regulatory Affairs, and Information Technology teams at Veristat. With more than 25 years of clinical research experience and demonstrated success in developing and growing global teams, she will ensure the delivery of operational consistency and excellence to our clients who are preparing, conducting, analyzing, reporting and submitting clinical trial data to the regulatory agencies.
Alecia has a broad background in executive and operational leadership from study start-up through submission activities at various global CROs including Chiltern, Charles River Labs, and IQVIA. Throughout her career, she has supported global clinical trials across the following therapeutic areas: Infectious Disease, Oncology, Respiratory, Vaccines, Endocrinology, and Cardiovascular Disease.
She earned her Bachelor of Science in Biology from the University of North Carolina at Wilmington.

Lindsey Lukis
Executive Vice President, Talent & Culture
Lindsey Lukis is the Executive Vice President of Talent and Culture at Veristat, responsible for the people related programs and initiatives that allow Veristat to achieve its strategic growth plans. Lindsey leads the Talent and Culture team to attract, develop, and retain Veristat’s human capital; she is also responsible for the Company’s short and long term people strategies, talent development, and fostering a culture of engagement, agility, and partnership.
Lindsey joined Veristat in 2015 with prior experience in the retail, financial services, and energy industries, having worked for companies such as Bose Corporation and The Hanover Insurance Group. She brings more than 15 years of progressive experience in the field of human resources with a particular focus/expertise in talent acquisition and management. Lindsey holds a B.S. from James Madison University, focused in Organizational Communication Studies and Training and Development. Outside of work Lindsey enjoys a full home life with her young family, practicing yoga, running and perhaps her most important role - hockey mom.

Mark Ammann, Pharm.D.
Senior Vice President, Regulatory Affairs
Mark Ammann is the Senior Vice President of Regulatory Affairs at Veristat. Prior to Veristat Mark was the owner and President of Catalyst Regulatory Services and established a successful Regulatory Affairs consulting practice at United BioSource Corporation where he served as Vice President of Regulatory Affairs and provided strategic regulatory consulting to a range of clients from start-up pharmaceutical companies to large multinational corporations. Prior to starting his consulting career, Mark held positions with increasing levels of responsibility within Regulatory Affairs for 18 years at three major pharmaceutical companies (Novartis, Pharmacia and Pfizer).
Mark is a recognized leader in the regulatory affairs community with an extensive knowledge of regulatory issues and the overall pharmaceutical development process. His excellent analytical, communication and negotiation skills have been used to effectively prepare and lead teams through many challenging health authority interactions.
Mark received his Doctor of Pharmacy degree from the University of Michigan.

Mara Holinger, PhD, RAC
Vice President, Regulatory Affairs
Dr. Holinger is the Vice President of Regulatory Affairs at Veristat, a role in which she oversees the Regulatory consulting and operations team. She works with sponsors to plan their programs and navigate the regulatory submission process throughout the entire drug development life-cycle.
Mara earned her PhD in Molecular Microbiology from Tufts University School of Medicine and began her career as a lead scientist in anti-cancer research. She provides pharmaceutical, biotech and medical device firms with strategic consulting to prepare their regulatory pathway; to design their clinical program and trials; to perform gap analysis for Chemistry, Manufacturing and Controls (CMC) and preclinical reporting and to write regulatory applications. Additionally, she is an expert in regulatory agency meeting preparation, moderation and logistical support, and serves as an Authorized Regulatory Representative and US Agent. Mara has written, reviewed or provided oversight for more than 20 Investigational New Drug Applications (INDs), multiple Orphan Drug Designation (ODD) applications, breakthrough designation applications, special protocol assessments, fast track applications and several New Drug Applications.

Lianne Riley
Vice President, European Clinical Operations
Lianne Riley is the Vice President of European Clinical Operations at Veristat. In this role, Lianne oversees EU patient recruitment, site engagement, site monitoring, and site management teams. With 30 years of experience running clinical trials, she excels in project management, site and patient access, and clinical study conduct.
She joined Veristat through the acquisition of The Clinical Trial Company, a UK-based CRO and held the role of Head of Clinical Operations. She has worked in clinical operations, project management and leadership roles at various clinical research organizations (CROs) and pharmaceutical firms including AstraZeneca, GlaxoSmithKline, PPD, and Syneos Health.

Rita Cassola, B.Pharm. (Hons.)
Vice President of Pharmacovigilance
Rita recently joined Veristat through its acquisition of Certus PV. In her new role at Veristat, she will lead and expand the pre-approval and post-marketing pharmacovigilance and safety surveillance team.
Rita is a registered pharmacist with over 20 years of experience in global and Canadian pharmacovigilance. Her experience includes more than a decade of senior PV consultancy and ten years in increasingly senior PV roles within the pharmaceutical industry.
Before co-founding Certus PV Services, Rita spent five years in increasingly senior consultant roles at CanReg/OptumInsight. In her Senior Director PV role, Rita routinely provided expert pharmacovigilance guidance to pharmaceutical companies in Canada. She acted as the lead auditor in several audits and assisted companies in preparing for GVP inspections. Rita was also instrumental in setting up pharmacovigilance systems for Canadian companies. Rita’s previous work experience includes ten years at Novartis Consumer Health in Canada and Switzerland, including a global senior management role in aggregate reporting and case processing.
Rita is a recognized pharmacovigilance leader and educator, having presented at PV conferences/webinars organized by professional industry associations. She is a member of the Drug Information Association (DIA) and the Canadian Pharmacovigilance Network and has presented at several conferences/webinars organized by these professional associations.

Agnes Jankowicz, M.Sc.
Vice President of Pharmacovigilance
Agnes recently joined Veristat through its acquisition of Certus PV. In her new role at Veristat, she will lead and expand the pre-approval and post-marketing pharmacovigilance and safety surveillance team.
Agnes has started her career in the pharmaceutical industry over 20 years ago.
She has 17 years of experience in global and Canadian pharmacovigilance within the pharmaceutical industry and senior PV consultancy roles. In addition to pharmacovigilance, Agnes's expertise includes medical information, regulatory affairs, and pharmaceutical sales.
Before co-founding Certus PV, Agnes was a Director, PV at OptumInsight. In this leadership function, she headed the PV & MI Department at one of Canada's ten most prominent pharmaceutical companies. She provided strategic PV & MI advice for over 15 other clients. Having led numerous PV audits of contractual partners and vendors on behalf of Marketing Authorisation Holders, Agnes is an expert PV auditor. She is also a recognized PV trainer. Her extensive industry experience includes nine years in PV & MI roles at Bayer Inc. Agnes is a member of the Drug Information Association (DIA) as well as a member of the Canadian Pharmacovigilance Network.
She holds an MSc degree in pharmacology and toxicology.

Montserrat (Montse) Barceló Riera, M.D.
Vice President, Europe
As Vice President, Europe at Veristat, Dr. Barceló will drive the strategic European growth plan and expand services through organic and acquisition growth initiatives to ensure customer success. Veristat will continue to broaden its customer base and clinical operations, biometrics, pharmacovigilance, and regulatory operations throughout Europe. Montse will ensure that all growth maintains the high-quality scientific standards that the Company provides clients across its North American, Taiwan, and European geographies.
Dr. Barceló received her medical doctor degree from the University of Barcelona in Spain in General Medicine and Surgery. She started her pharma services career as the General Manager for Spain at Clinical Data Care, a Swedish data management CRO. Later in her career, she joined the Scandinavian CRO, TFS, as Regional Managing Director, ascending to the role of Global Chief Operating Officer, where she was responsible for 18 countries globally and more than 600 clinical research professionals across 23 affiliate locations.
Team Member Name
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque sed ligula non velit laoreet dictum. Suspendisse potenti. Nullam at diam vel urna gravida posuere. Maecenas at viverra lacus. Duis sed lectus ex. Praesent sed risus tellus. Nulla venenatis consequat elit, vitae posuere arcu finibus a.
Sed condimentum facilisis facilisis. Ut a placerat lectus. Mauris eros sem, semper ac leo sed, egestas pellentesque augue. Donec libero eros, venenatis non nunc eu, euismod euismod elit. Nullam efficitur, ipsum vitae tincidunt congue, nunc diam pretium elit, sed dictum augue purus at erat. Aenean eu cursus sapien. Sed quis quam nec urna rutrum feugiat. Nunc sollicitudin metus sed aliquam euismod. Nulla feugiat viverra neque malesuada mollis. Etiam leo est, cursus non erat ac, finibus dignissim tellus. Etiam ac diam porttitor, blandit magna at, ultricies neque. Praesent interdum justo lacus, vel lobortis est pellentesque a. Phasellus vulputate felis sagittis congue malesuada.
Praesent posuere ligula enim, quis vulputate dolor vulputate in. Integer ipsum enim, aliquam at nulla sed, facilisis consequat odio. Fusce porta quam sit amet ex mollis faucibus. In feugiat, mi et pretium mollis, risus lacus feugiat nisl, eu commodo tortor enim eu orci. Aliquam erat volutpat. Suspendisse efficitur elit a posuere tincidunt. Mauris vel congue nisi. Nunc a eros eu tellus tristique facilisis. Quisque accumsan urna ac libero mattis convallis. Curabitur rutrum quis odio id luctus. Sed luctus, urna vitae eleifend vestibulum, nisl orci faucibus eros, ut sagittis quam urna id sem. Suspendisse volutpat felis nec diam feugiat, in sagittis erat varius. Pellentesque tincidunt ultrices fermentum.